Rothschild & Co Redburn analyst Jamie Clark initiated coverage of West Pharmaceutical (WST) with a Buy rating and $311 price target which represents 18% potential upside. The firm believes West is passed the post-COVID demand headwinds and is now on track to return to mid-teens earnings growth from 2026. The company’s growth is driven by continued demand for biologic drugs, an increasing proportion of biopharma industry revenues, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WST:
- West Pharmaceutical Announces Departure of Senior VP
- AI Analyst Is Bullish on These 3 “Strong Buy” Healthcare Stocks, 9/2/25
- West Pharmaceutical price target raised to $320 from $285 at UBS
- West Pharmaceutical Services Reports Strong Q2 2025 Results
- West Pharmaceutical Services’ Earnings Call Highlights Strong Growth